The stock of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has increased by 7.64% when compared to last closing price of $17.54. Despite this, the company has experienced a 17.34% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-07-08 that PASADENA, Calif.–(BUSINESS WIRE)—- $arwr–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for homozygous familial hypercholesterolemia (HoFH), a rare genetic condition that leads to severely elevated LDL-cholesterol and early onset cardiovascular disease. Zodasiran is the fourth investigational.
Is It Worth Investing in Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Right Now?
Moreover, the 36-month beta value for ARWR is 0.94. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 3 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for ARWR is 115.20M and currently, short sellers hold a 11.01% of that float. On July 10, 2025, ARWR’s average trading volume was 1.76M shares.
ARWR’s Market Performance
ARWR’s stock has seen a 17.34% increase for the week, with a 12.31% rise in the past month and a 84.20% gain in the past quarter. The volatility ratio for the week is 5.01%, and the volatility levels for the past 30 days are at 4.85% for Arrowhead Pharmaceuticals Inc The simple moving average for the past 20 days is 15.85% for ARWR’s stock, with a 6.01% simple moving average for the past 200 days.
Analysts’ Opinion of ARWR
Many brokerage firms have already submitted their reports for ARWR stocks, with Goldman repeating the rating for ARWR by listing it as a “Neutral.” The predicted price for ARWR in the upcoming period, according to Goldman is $31 based on the research report published on June 05, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see ARWR reach a price target of $29. The rating they have provided for ARWR stocks is “Buy” according to the report published on December 04th, 2023.
Citigroup gave a rating of “Neutral” to ARWR, setting the target price at $33 in the report published on September 19th of the previous year.
ARWR Trading at 21.31% from the 50-Day Moving Average
After a stumble in the market that brought ARWR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.92% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARWR starting from Anzalone Christopher Richard, who sale 50,800 shares at the price of $11.49 back on Apr 11 ’25. After this action, Anzalone Christopher Richard now owns 3,921,255 shares of Arrowhead Pharmaceuticals Inc, valued at $583,692 using the latest closing price.
Anzalone Christopher Richard, the Chief Executive Officer of Arrowhead Pharmaceuticals Inc, sale 50,000 shares at $10.87 during a trade that took place back on Apr 10 ’25, which means that Anzalone Christopher Richard is holding 3,972,055 shares at $543,500 based on the most recent closing price.
Stock Fundamentals for ARWR
Current profitability levels for the company are sitting at:
- -0.22 for the present operating margin
- 0.98 for the gross margin
The net margin for Arrowhead Pharmaceuticals Inc stands at -0.27. The total capital return value is set at -0.08. Equity return is now at value -24.67, with -11.39 for asset returns.
Currently, EBITDA for the company is -561.51 million with net debt to EBITDA at 3.09. When we switch over and look at the enterprise to sales, we see a ratio of 4.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.15.
Conclusion
To wrap up, the performance of Arrowhead Pharmaceuticals Inc (ARWR) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
